Loading...

NeuroVive Pharmaceutical

DB:NTP
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NTP
DB
SEK255M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • NeuroVive Pharmaceutical has significant price volatility in the past 3 months.
NTP Share Price and Events
7 Day Returns
0%
DB:NTP
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-46.4%
DB:NTP
-10.2%
DE Biotechs
-6%
DE Market
NTP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NeuroVive Pharmaceutical (NTP) 0% -2.5% -16.9% -46.4% -82.6% -95.5%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • NTP underperformed the Biotechs industry which returned -10.2% over the past year.
  • NTP underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
NTP
Industry
5yr Volatility vs Market

Value

 Is NeuroVive Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NeuroVive Pharmaceutical. This is due to cash flow or dividend data being unavailable. The share price is €0.118.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NeuroVive Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NeuroVive Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NTP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-0.87
OM:NVP Share Price ** OM (2019-04-18) in SEK SEK1.37
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NeuroVive Pharmaceutical.

DB:NTP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:NVP Share Price ÷ EPS (both in SEK)

= 1.37 ÷ -0.87

-1.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroVive Pharmaceutical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NeuroVive Pharmaceutical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NeuroVive Pharmaceutical's expected growth come at a high price?
Raw Data
DB:NTP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-27.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NeuroVive Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NeuroVive Pharmaceutical's assets?
Raw Data
DB:NTP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK1.06
OM:NVP Share Price * OM (2019-04-18) in SEK SEK1.37
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:NTP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:NVP Share Price ÷ Book Value per Share (both in SEK)

= 1.37 ÷ 1.06

1.3x

* Primary Listing of NeuroVive Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroVive Pharmaceutical is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess NeuroVive Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NeuroVive Pharmaceutical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NeuroVive Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-27.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NeuroVive Pharmaceutical expected to grow at an attractive rate?
  • Unable to compare NeuroVive Pharmaceutical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare NeuroVive Pharmaceutical's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • NeuroVive Pharmaceutical's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NTP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NTP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -27.9%
DB:NTP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts -77.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NTP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NTP Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 -174 -175 1
2020-12-31 1 -119 -114 2
2019-12-31 1 -101 -94 3
DB:NTP Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -64 -68
2018-09-30 2 -62 -68
2018-06-30 2 -64 -66
2018-03-31 0 -57 -63
2017-12-31 0 -58 -67
2017-09-30 0 -60 -66
2017-06-30 0 -55 -87
2017-03-31 0 -55 -76
2016-12-31 0 -57 -70
2016-09-30 0 -62 -63
2016-06-30 0 -66 -83
2016-03-31 3 -59 -87

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NeuroVive Pharmaceutical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • NeuroVive Pharmaceutical's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NTP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from NeuroVive Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NTP Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.58 -0.58 -0.58 1.00
2020-12-31 -0.49 -0.40 -0.58 2.00
2019-12-31 -0.59 -0.56 -0.62 2.00
DB:NTP Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -0.87
2018-09-30 -1.00
2018-06-30 -1.16
2018-03-31 -1.19
2017-12-31 -1.33
2017-09-30 -1.33
2017-06-30 -1.76
2017-03-31 -1.70
2016-12-31 -1.67
2016-09-30 -1.69
2016-06-30 -2.52
2016-03-31 -2.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NeuroVive Pharmaceutical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess NeuroVive Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NeuroVive Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NeuroVive Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NeuroVive Pharmaceutical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NeuroVive Pharmaceutical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NeuroVive Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NeuroVive Pharmaceutical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NeuroVive Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NeuroVive Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NTP Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.47 -68.37 14.45
2018-09-30 1.52 -68.29 13.49
2018-06-30 1.52 -66.41 13.20
2018-03-31 0.07 -63.19 12.47
2017-12-31 0.10 -66.73 12.42
2017-09-30 0.04 -66.10 13.91
2017-06-30 0.04 -86.92 15.00
2017-03-31 0.04 -76.25 15.38
2016-12-31 0.01 -70.24 15.28
2016-09-30 0.00 -62.91 14.20
2016-06-30 0.00 -82.66 16.03
2016-03-31 2.50 -86.70 4.77
2015-12-31 2.50 -90.12 15.56
2015-09-30 3.62 -99.61 15.97
2015-06-30 10.78 -49.39 12.44
2015-03-31 8.27 -46.99 14.56
2014-12-31 8.27 -42.55 10.35
2014-09-30 7.06 -34.78 9.56
2014-06-30 0.63 -37.73 8.55
2014-03-31 6.12 -27.37 10.90
2013-12-31 6.83 -22.33 6.50
2013-09-30 7.51 -18.52 5.34
2013-06-30 6.99 -15.80 5.34
2013-03-31 1.81 -16.78 7.19
2012-12-31 1.11 -14.87 4.57
2012-09-30 0.92 -12.63 6.26
2012-06-30 0.72 -11.29 7.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NeuroVive Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NeuroVive Pharmaceutical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NeuroVive Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NeuroVive Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NeuroVive Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NeuroVive Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NeuroVive Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NeuroVive Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NeuroVive Pharmaceutical has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NeuroVive Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NeuroVive Pharmaceutical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NeuroVive Pharmaceutical Company Filings, last reported 3 months ago.

DB:NTP Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 97.01 0.00 25.95
2018-09-30 116.51 0.00 38.37
2018-06-30 131.49 0.00 51.90
2018-03-31 92.80 0.00 15.76
2017-12-31 105.85 0.00 28.99
2017-09-30 115.94 0.00 35.44
2017-06-30 124.80 0.00 46.98
2017-03-31 146.93 0.00 67.29
2016-12-31 168.30 0.00 93.25
2016-09-30 182.39 0.00 112.89
2016-06-30 215.93 0.00 132.28
2016-03-31 149.86 0.00 78.75
2015-12-31 154.78 0.00 96.66
2015-09-30 161.97 0.00 116.97
2015-06-30 217.18 0.00 138.05
2015-03-31 172.71 0.00 104.74
2014-12-31 107.84 0.00 49.70
2014-09-30 123.85 0.00 58.94
2014-06-30 127.57 0.00 74.51
2014-03-31 141.36 0.00 97.10
2013-12-31 74.64 0.00 39.99
2013-09-30 50.09 0.00 15.00
2013-06-30 56.83 0.00 22.97
2013-03-31 58.43 0.00 27.72
2012-12-31 63.04 0.00 37.18
2012-09-30 68.23 0.00 43.57
2012-06-30 72.06 0.00 49.42
  • NeuroVive Pharmaceutical has no debt.
  • NeuroVive Pharmaceutical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NeuroVive Pharmaceutical has less than a year of cash runway based on current free cash flow.
  • NeuroVive Pharmaceutical has less than a year of cash runway if free cash flow continues to reduce at historical rates of -10.8% each year.
X
Financial health checks
We assess NeuroVive Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NeuroVive Pharmaceutical has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NeuroVive Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NeuroVive Pharmaceutical dividends. Estimated to be 0% next year.
If you bought €2,000 of NeuroVive Pharmaceutical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NeuroVive Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NeuroVive Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NTP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NTP Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NeuroVive Pharmaceutical has not reported any payouts.
  • Unable to verify if NeuroVive Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NeuroVive Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NeuroVive Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of NeuroVive Pharmaceutical's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess NeuroVive Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NeuroVive Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NeuroVive Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NeuroVive Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Erik Kinnmann
COMPENSATION SEK3,219,000
AGE 60
TENURE AS CEO 3.1 years
CEO Bio

Mr. Erik Kinnmann, M.D., Ph.D., M.B.A., Assoc. Prof. has been the Chief Executive Officer of NeuroVive Pharmaceutical AB since March 14, 2016. Mr. Kinnmann served as the Chief Medical Officer of Infant Bacterial Therapeutics AB. He served as Vice President of Investor Relations, Director of Business Strategy and Medical Advisor of Neurology at PledPharma AB. He served as the Chief Strategic Officer and Vice President of Investor Relations & Public Affairs of Swedish Orphan Biovitrum AB since March 2008 and served as its Head of Investor Relations & Public Affairs and Executive Vice President. He has 19 years experience in the pharmaceutical industry, including relevant knowledge and experience on orphan drug development (AstraZeneca, SOBI, Wilson Therapeutics, Biocrine, Sanofi, Pfizer). He has an extensive experience from the financial sector. He has an impressive knowledge and combined pharmaceutical industry and health care financial sector experience. Mr. Kinnmann held a number of senior leadership positions within AstraZeneca, Sanofi-Synthelabo Scandinavia and Parke-Davies/Warner-Lambert Norden AB. He served as the Head of a health care sector analysis team of Danske Securities AB. Prior to that, he served as a Health Care Fund Manager of Aragon Fondkommission AB. He served as an Associate Professor in experimental and clinical pain research at Karolinska Institutet. Mr. Kinnmann holds an MBA from the Stockholm School of Economics and Ph.D. from the Karolinska Institutet. He is a MD, Board Certified in Neurology and Pain Management.

CEO Compensation
  • Erik's compensation has increased whilst company is loss making.
  • Erik's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NeuroVive Pharmaceutical management team in years:

3.3
Average Tenure
49.5
Average Age
  • The tenure for the NeuroVive Pharmaceutical management team is about average.
Management Team

Erik Kinnmann

TITLE
Chief Executive Officer
COMPENSATION
SEK3M
AGE
60
TENURE
3.1 yrs

Catharina Johansson

TITLE
CFO & VP of Investor Relations
AGE
51
TENURE
5.3 yrs

Eskil Elmér

TITLE
Chief Scientific Officer & VP of Discovery
COMPENSATION
SEK247K
AGE
48
TENURE
19.3 yrs

Daniel Schale

TITLE
Director of Communications
TENURE
1.5 yrs

Magnus Hansson

TITLE
Chief Medical Officer and VP of Preclinical & Clinical Development
AGE
42
TENURE
3.3 yrs

Lars Vedin

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the NeuroVive Pharmaceutical board of directors in years:

1.8
Average Tenure
59
Average Age
  • The average tenure for the NeuroVive Pharmaceutical board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Laskow-Pooley

TITLE
Chairman of the Board
COMPENSATION
SEK230K
AGE
64
TENURE
1.4 yrs

David Bejker

TITLE
Director
COMPENSATION
SEK219K
AGE
43
TENURE
2.3 yrs

Jan Törnell

TITLE
Director
COMPENSATION
SEK175K
AGE
58
TENURE
2.3 yrs

Denise Goode

TITLE
Director
AGE
60
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Dec 18 Buy Erik Kinnmann Individual 21. Dec 18 27. Dec 18 117,901 €0.13 €15,001
19. Dec 18 Buy Magnus Hansson Individual 19. Dec 18 19. Dec 18 20,000 €0.13 €2,531
X
Management checks
We assess NeuroVive Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NeuroVive Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.

Details
Name: NeuroVive Pharmaceutical AB
NTP
Exchange: DB
Founded: 2000
SEK24,367,538
185,952,591
Website: http://www.neurovive.com
Address: NeuroVive Pharmaceutical AB
Medicon Village,
Scheelevägen 2,
Lund,
Skåne County, 223 81,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM NVP Share Capital OMX Nordic Exchange Stockholm SE SEK 03. Oct 2008
OTCPK NEVP.F Share Capital Pink Sheets LLC US USD 03. Oct 2008
DB NTP Share Capital Deutsche Boerse AG DE EUR 03. Oct 2008
LSE 0QDU Share Capital London Stock Exchange GB SEK 03. Oct 2008
BATS-CHIXE NVPS Share Capital BATS 'Chi-X Europe' GB SEK 03. Oct 2008
Number of employees
Current staff
Staff numbers
10
NeuroVive Pharmaceutical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.